#LCSM Chat 5/31/18: Lung Cancer at ASCO 2018
For the upcoming #LCSM chat on Thursday, 5/31 at 8 PM Eastern (5 PM Pacific), we’re going to preview some of the key abstracts in lung cancer and mesothelioma that will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago in early June. This meeting brings together over 38,000 cancer specialists every year to review thousands of presentations. Nobody can see it all, and one important aspect of not being overwhelmed is knowing what should be the focus of your attention. Dr. Jack West has compiled two… Read More
#LCSM Chat Topic 5/3/18: What Defines a “Quality” #LungCancer Treatment Center? Thoughts from the Frontline
Our topic for the #LCSM Tweet Chat on Thursday, May 3rd (5 PM Pacific/8 PM Eastern) is “What Defines a “Quality” #LungCancer Treatment Center? Thoughts from the Frontline.” The moderator for this chat is Dr. David Tom Cooke (@DavidCookeMD). Recently the Centers for Medicaid and Medicare Services (CMS) announced it would cover next-generation sequencing (NGS) for US patients with stage III or IV lung cancer when ordered by a physician and performed in a CLIA-certified laboratory. This decision makes broad genomic testing to available to many more patients. Having increased access to… Read More
#LCSM Chat Topic 22-Feb-2018: Lung cancer research–Why we need it and how we can get more
“Cancer research” is a broad term that encompasses everything from basic bench science, to translational research on patient-derived tumor specimens, to clinical trials, to studies on patient centered outcomes. While it is obvious to all of us in the lung cancer community that research is critical to improving patient outcomes, lung cancer remains underfunded compared to other common cancers. Several different mechanisms exist to fund cancer research, including private philanthropy, Big Pharma, not-for-profit cancer research and advocacy groups, and government organizations including the DOD and NIH/NCI among others. Given funding imbalances, it… Read More
You must be logged in to post a comment.